Trial Radar AI | ||
|---|---|---|
Clinical Trial NCT07477730 (LIAQ) for Total Knee Arthroplasty is not yet recruiting. See the Trial Radar Card View and AI discovery tools for all the details. Or ask anything here. | ||
One study matched filter criteria
Card View
Local Infiltration Analgesia Versus Quadruple Nerve Blocks in Total Knee Arthroplasty. (LIAQ) 80 Randomized Open-Label
Clinical Trial NCT07477730 (LIAQ) is an interventional study for Total Knee Arthroplasty and is currently not yet recruiting. Enrollment is planned to begin on 1 June 2026 and continue until the study accrues 80 participants. Led by CMC Ambroise Paré, this study is expected to complete by 1 February 2028. The latest data from ClinicalTrials.gov was last updated on 17 March 2026.
Brief Summary
Total knee arthroplasty (TKA) is one of the most common orthopedic surgical procedures and is associated with severe pain in the immediate postoperative period, thus limiting early recovery.
Optimal postoperative pain management after TKA is not fully defined. While multimodal analgesia is standard, the choice of associated regional anesthesia techniques is debated.
Local infiltration analgesia (LIA) is widely used...
Show MoreDetailed Description
In the pre-anaesthesia room, after the implementation of classical monitoring with an oxygen mask and a peripheral venous catheter, all patients will receive an antibioprophylaxis according to the recommendations of the SFAR (French Society of Anesthesia & Intensive Care Medecine) and an injection of 10 mg of IV dexamethasone.
The surgical procedure is a total knee arthroplasty (TKA) performed under general anesthe...
Show MoreOfficial Title
Local Infiltration Analgesia Versus Quadruple Nerve Blocks in Total Knee Arthroplasty: a Randomized Controlled Trial.
Conditions
Total Knee ArthroplastyOther Study IDs
- LIAQ
- 2025/02
NCT ID Number
Start Date (Actual)
2026-06-01
Last Update Posted
2026-03-17
Completion Date (Estimated)
2028-02-01
Enrollment (Estimated)
80
Study Type
Interventional
PHASE
N/A
Status
Not yet recruiting
Keywords
Knee arthroplasty
Local Infiltration Analgesia
Regional anesthesia
Ropivacaine
Postoperative analgesia
Pain management
Opioids
Local Infiltration Analgesia
Regional anesthesia
Ropivacaine
Postoperative analgesia
Pain management
Opioids
Primary Purpose
Other
Design Allocation
Randomized
Interventional Model
Parallel
Masking
Double
Arms / Interventions
| Participant Group/Arm | Intervention/Treatment |
|---|---|
Active ComparatorLIA group Local infiltration analgesia | Surgical local infiltration Injection of 150 mL of ropivacaine 0.2% into periarticular tissues according to a standardized sequence, including the posterior capsule, collateral ligaments, quadriceps, patellar tendon, capsule and subcutaneous tissue before wound closure |
ExperimentalQuadruple nerve blocks group Femoral, sciatic, obturator and lateral femoral cutaneous nerve blocks | Obturator nerve block Injection of 20 mL of 0.1% ropivacaine between the adductor magnus and adductor brevis muscles and between the adductor brevis and pectineus muscles Femoral nerve block Injection of 15 mL of 0.1% ropivacaine under the fascia iliaca, with the patient in supine position Sciatic nerve block Injection of 20 mL of 0.1% ropivacaine in the subgluteal space via a lateral approach, with the patient in prone position Lateral femoral cutaneous nerve block Injection of 5 mL of 0.1% ropivacaine lateral to the sartorius muscle |
Primary Outcome Measures
Secondary Outcome Measures
| Outcome Measure | Measure Description | Time Frame |
|---|---|---|
Total opioid consumption within 24 hours | Total cumulative opioid consumption during the first 24 hours, expressed in oral morphine equivalents (OME, mg), including intraoperative and postoperative opioid administration. | From start of surgery (t0) to 24 hours postoperatively |
| Outcome Measure | Measure Description | Time Frame |
|---|---|---|
Intraoperative anesthetic consumption | Total intraoperative consumption of propofol (mg) | During surgery |
Intraoperative opioid consumption | Total intraoperative consumption of sufentanil (µg) | During surgery |
Intraoperative hypertension events | Occurrence of intraoperative hypertension episodes defined as systolic blood pressure \>160 mmHg | During surgery |
Intraoperative hypotension events | Occurrence of intraoperative hypotension episodes defined as systolic blood pressure \<90 mmHg | During surgery |
Postoperative pain intensity | Pain intensity at rest assessed using a verbal rating scale (VRS, 0-10) ranging from 0 to 10 (0=no pain, 10=worst possible pain), recorded every 6 hours during the first 48 postoperative hours | Up to 48 hours postoperatively |
Total opioid consumption within 48 hours | Total cumulative opioid consumption during the first 48 hours, expressed in oral morphine equivalents (OME, mg), including intraoperative and postoperative opioid administration. | From start of surgery (t0) to 48 hours postoperatively |
Opioid-related adverse effects | Incidence of nausea and vomiting, somnolence, constipation, acute urinary retention, pruritus, and disorientation. | Up to 48 hours postoperatively |
Quadricep motor function | Quadriceps muscle strength assessed on a 3-point scale: 0 = paralysis; 1 = paresis; 2 = normal contraction | Postoperative days 0, 1, and 2 |
Foot elevator muscle motor function | Ankle dorsiflexor muscle strength assessed on a 3-point scale: 0 = paralysis; 1 = paresis; 2 = normal contraction | Postoperative days 0, 1, and 2 |
Ability to stand and walk | 4-point scale: 0 = unable to get up; 1 = able to get up but unable to walk; 2 = able to walk \<50 m; 3 = able to walk ≥50 m | Postoperative days 0, 1, and 2 |
Mobility and balance | Timed Up and Go (TUG) test, measured in seconds | Postoperative days 0, 1, and 2 |
Functional Independence | Functional Independence Measure (FIM), with total scores ranging from 18 to 126, where higher scores indicating greater independence | Postoperative days 0, 1, and 2 |
Postoperative falls | Occurrence of any fall defined as an unintentional event resulting in the patient coming to rest on the ground or a lower level | Postoperative days 0, 1, and 2 |
Hospital readmission within 30 days | Any hospital readmission within 30 days after surgery, regardless of cause | 30 days postoperatively |
Functional outcome at 60 days | Short-form WOMAC index focused on physical function), with total scores ranging from 0 to 28, where higher scores indicating greater functional impairment | 60 days postoperatively |
Participation Assistant
Eligibility Criteria
Eligible Ages
Adult, Older Adult
Minimum Age
18 Years
Eligible Sexes
All
- Patients undergoing primary total knee arthroplasty under general anesthesia (laryngeal mask airway)
- Fully autonomous at home
- Planned discharge to home
- Consent for participation
- Affiliation to a social security system
- Preoperative opioid use
- Chronic pain syndrome
- Valgus contraindicating sciatic nerve block
- Contraindication to any drugs used in the protocol
- Contraindication to laryngeal mask airway
- Pregnant or breastfeeding women
- Patients under protection of the adults (guardianship, curators or safeguard of justice)
CMC Ambroise ParéStudy Central Contact
Contact: Philippe MARTY, MD, 05 62 13 29 97, [email protected]
1 Study Locations in 1 Countries
Haute-Garonne
Clinique Médipôle Garonne, Toulouse, Haute-Garonne, 31036, France
Clément CHASSERY, MD, Contact, 05 62 13 29 97, [email protected]
Clément CHASSERY, MD, Principal Investigator